News

The collaboration brings together TES Pharma, a research-based biotech company led by Professor Roberto Pellicciari (Scientific Co-Founder of Intercept Pharmaceuticals, Inc) with state of the art research facilities

The collaboration will focus on the development of a portfolio of AGTC’s therapeutic programs, including both a clinical stage candidate and a pre-clinical candidate for orphan diseases of

KTE-C19 is an investigational therapy in which a patient’s T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target CD19, a protein expressed

Rociletinib is the Company’s novel, oral targeted covalent (irreversible) mutant-selective inhibitor of EGFR in development for the treatment of NSCLC in patients with initial activating EGFR mutations, as

Alchemia Oncology Pty Limited has a robust collection of clinical and pre-clinical oncology assets, which include the HyACT Drug Delivery Platform, a portfolio of targeted therapeutics which are

New companies Lupin and Strides Arcolab recently signed agreements to produce dolutegravir (DTG), a promising new HIV medicine the MPP licensed from ViiV Healthcare two months after its

The fact that R-Japan received the license of cell processing facility through the auditing from Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, 2015 two months after

Breckenridge and Alembic filed their Paragraph IV ANDA on the first-to-file date and expect to share 180-day exclusivity with other ANDA first filers. Alembic Pharmaceuticals Limited is the

RHB-104 is an antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. Currently, RHB-104 is undergoing a first Phase III study for Crohn’s